FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Nick Bansback

Research Profile

Disorders

Rheumatoid Arthritis

Activities & Behaviors

Chemicals & Drugs

Concepts & Ideas

Procedures

Patient Medication Knowledge

Co-author Network

Publications

TOP 3
Mohsen Sadatsafavi; Zafar Zafari; Nick Bansback; Mehdi Najafzadeh; Carlo Marra
Need for speed: an efficient algorithm for calculation of single-parameter expected value of partial perfect information.
Brendan Mulhern; Donna Rowen; Nick Bansback; John Brazier; Nancy Devlin; Louise Longworth; Aki Tsuchiya
Binary choice health state valuation and mode of administration: head-to-head comparison of online and CAPI.
WG Dixon; Nick Bansback
Understanding the side effects of glucocorticoid therapy: shining a light on a drug everyone thinks they know.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Nick Bansback (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Mohsen Sadatsafavi; Zafar Zafari; Nick Bansback; Mehdi Najafzadeh; Carlo Marra
Need for speed: an efficient algorithm for calculation of single-parameter expected value of partial perfect information.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2013;16(2):438-48.
2013: Brendan Mulhern; Donna Rowen; Nick Bansback; John Brazier; Nancy Devlin; Louise Longworth; Aki Tsuchiya
Binary choice health state valuation and mode of administration: head-to-head comparison of online and CAPI.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2013;16(1):104-13.
2012: WG Dixon; Nick Bansback
Understanding the side effects of glucocorticoid therapy: shining a light on a drug everyone thinks they know.
Annals of the rheumatic diseases 2012;71(11):1761-4.
2012: Fergal P Mills; Jean B Nachega; Bohdan Nosyk; Sanni Yaya; Nick Bansback; Nathan Ford; Edward J Mills
Earlier initialization of highly active antiretroviral therapy is associated with long-term survival and is cost-effective: findings from a deterministic model of a 10-year Ugandan cohort.
Journal of acquired immune deficiency syndromes (1999) 2012;61(3):364-9.
2012: Nicole W Tsao; Kam Shojania; Nick Bansback; Carlo A Marra
The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis.
Best practice & research. Clinical rheumatology 2012;26(5):659-76.
2012: Wei Zhang; Nick Bansback; Judy A Chiu; Aslam H Anis
An update on the measurement of productivity losses due to rheumatoid diseases.
Best practice & research. Clinical rheumatology 2012;26(5):585-97.
2012: Nick Bansback; Daphne Guh; Sonia Sizto; Aslam H Anis
The effect of direct-to-consumer genetic tests on anticipated affect and health-seeking behaviors: a pilot survey.
Genetic testing and molecular biomarkers 2012;16(10):1165-71.
2012: Corneliu Bolbocean; Dean A Regier; Mohsen Sadatsafavi; David G T Whitehurst; Nick Bansback; Stirling Bryan
Response to 'Marginal costs of hospital-acquired conditions: information for priority-setting for patient safety programmes and research', Jackson et al., Journal of Health Services Research & Policy 2011;16:141-6.
Journal of health services research & policy 2012;17(2):127.
2012: Elena Nikiphorou; Peter Williams; Nick Bansback; Josh Dixey; Daphne Guh; Wei Zhang; Adam Young
Work disability rates in RA. Results from an inception cohort with 24 years follow-up.
Rheumatology (Oxford, England) 2012;51(2):385-92.
2012: Nick Bansback; Daphne Guh; Patrick Kiely; David Walsh; Richard Williams; Aslam Anis; Wei Zhang; Adam Young
Factors associated with absenteeism, presenteeism and activity impairment in patients in the first years of RA.
Rheumatology (Oxford, England) 2012;51(2):375-84.
2012: Nick Bansback; John Brazier; Aki Tsuchiya; Aslam Anis
Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies.
PloS one 2012;7(2):e31115.
2012: Wei Zhang; Nick Bansback; Annelies Boonen; Johan L Severens; Aslam H Anis
Development of a composite questionnaire, the valuation of lost productivity, to value productivity losses: application in rheumatoid arthritis.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2012;15(1):46-54.
2012: Nick Bansback; John Brazier; Aki Tsuchiya; Aslam Anis
Using a discrete choice experiment to estimate health state utility values.
Journal of health economics 2012;31(1):306-18.
2011: Jonathan Tosh; Allan Wailoo; Alan Brennan; Nick Bansback
The Sheffield rheumatoid arthritis health economic model.
Rheumatology (Oxford, England) 2011;50 Suppl 4():iv26-31.
2011: Wei Zhang; Nick Bansback; Jacek Kopec; Aslam H Anis
Measuring time input loss among patients with rheumatoid arthritis: validity and reliability of the Valuation of Lost Productivity questionnaire.
Journal of occupational and environmental medicine / American College of Occupational and Environmental Medicine 2011;53(5):530-6.
2011: Aslam H Anis; Nick Bansback; Sonia Sizto; Shiraz R Gupta; Mary Kaye Willian; Steve R Feldman
Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
The Journal of dermatological treatment 2011;22(2):65-74.
2011: Carlo A Marra; Nick Bansback; Aslam H Anis; Kamran Shojania
Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis.
Clinical rheumatology 2011;30 Suppl 1():S9-18.
2011: Edward J Mills; Andy Mtambo; Jean B Nachega; Mark Alberton; Christopher G Au-Yeung; Nick Bansback; Ivy Lynn Bourgeault; Amy Hagopian; Robert S Hogg; Steve Kanters; Samuel Luboga; Nathan Ford
The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis.
BMJ (Clinical research ed.) 2011;343():d7031.
2011: Edward J Mills; Milo Puhan; Kristian Thorlund; Nick Bansback; Isabella Ghement; Steven Kelly; James Wright
Multiple treatment comparison meta-analyses: a step forward into complexity.
Clinical epidemiology 2011;3():193-202.
2011: Wei Zhang; Nick Bansback; Aslam H Anis
Measuring and valuing productivity loss due to poor health: A critical review.
Social science & medicine (1982) 2011;72(2):185-92.
2010: Axel Finckh; Nick Bansback; Matthew H Liang
Cost-effectiveness of biologics in early rheumatoid arthritis.
Annals of internal medicine 2010;152(5):333-4; author reply 334.
2010: Jacek A Kopec; Eric C Sayre; W M Flanagan; P Fines; Jolanda Cibere; Md M Rahman; Nick Bansback; Aslam H Anis; Joanne M Jordan; B Sobolev; jaafar Aghajanian; W Kang; Nelson V Greidanus; Donald S Garbuz; Gillian A Hawker; E M Badley
Development of a population-based microsimulation model of osteoarthritis in Canada.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2010;18(3):303-11.
2010: Wei Zhang; Nick Bansback; Annelies Boonen; Adam Young; Amitabh Singh; Aslam H Anis
Validity of the work productivity and activity impairment questionnaire--general health version in patients with rheumatoid arthritis.
Arthritis research & therapy 2010;12(5):R177.
2010: Aslam H Anis; W Zhang; Nick Bansback; Daphne P Guh; Z Amarsi; C Laird Birmingham
Obesity and overweight in Canada: an updated cost-of-illness study.
Obesity reviews : an official journal of the International Association for the Study of Obesity 2010;11(1):31-40.
2009: Axel Finckh; Nick Bansback; Carlo A Marra; Aslam H Anis; Kaleb Michaud; Stanley Lubin; Marc White; Sonia Sizto; Matthew H Liang
Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Annals of internal medicine 2009;151(9):612-21.
2009: Camilla L Wong; Nick Bansback; Philip E Lee; Aslam H Anis
Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2009;36(6):735-9.
2009: Richard M Nixon; Anthony O'Hagan; Jeremy Oakley; Jason Madan; John W Stevens; Nick Bansback; Alan Brennan
The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.
Pharmaceutical statistics 2009;8(4):371-89.
2009: Bohdan Nosyk; Huiying Sun; Nick Bansback; Daphne P Guh; Xin Li; Paul Barnett; Ahmed Bayoumi; Susan Griffin; Vilija Joyce; Mark Holodniy; Doug K Owens; Aslam H Anis
The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2009;18(7):815-24.
2009: Aslam H Anis; Bohdan Nosyk; Huiying Sun; Daphne P Guh; Nick Bansback; Xin Li; Paul G Barnett; Vilija Joyce; Kathleen M Swanson; Tassos C Kyriakides; Mark Holodniy; William Cameron; Sheldon T Brown
Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events.
Journal of acquired immune deficiency syndromes (1999) 2009;51(5):631-9.
2009: S Sizto; Nick Bansback; S R Feldman; M K Willian; Aslam H Anis
Economic evaluation of systemic therapies for moderate to severe psoriasis.
The British journal of dermatology 2009;160(6):1264-72.
2009: Richard M Nixon; Nick Bansback; John W Stevens; Alan Brennan; Jason Madan
Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis.
Pharmaceutical statistics 2009;8(2):150-62.
2009: Nick Bansback; Carlo A Marra
Now that we know what's BeSt, what is good value for the money?
Arthritis and rheumatism 2009;61(3):289-90.
2009: Nick Bansback; Carlo A Marra; Axel Finckh; Aslam Anis
The economics of treatment in early rheumatoid arthritis.
Best practice & research. Clinical rheumatology 2009;23(1):83-92.
2009: Nick Bansback; Sonia Sizto; Huiying Sun; Steven Feldman; Mary Kaye Willian; Aslam Anis
Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis.
Dermatology (Basel, Switzerland) 2009;219(3):209-18.
2009: Daphne P Guh; Wei Zhang; Nick Bansback; Zubin Amarsi; C Laird Birmingham; Aslam H Anis
The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis.
BMC public health 2009;9():88.
2009: Nick Bansback; Roberta Ara; Sue Ward; Aslam H Anis; Hyon K Choi
Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis.
PharmacoEconomics 2009;27(1):25-37.
2008: Nick Bansback; Huiying Sun; Daphne P Guh; Xin Li; Bohdan Nosyk; Susan Griffin; Paul G Barnett; Aslam H Anis
Impact of the recall period on measuring health utilities for acute events.
Health economics 2008;17(12):1413-9.
2008: Wei Zhang; Nick Bansback; Daphne Guh; Xin Li; Bohdan Nosyk; Carlo A Marra; Aslam H Anis
Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis.
The Journal of rheumatology 2008;35(9):1729-36.
2008: Nick Bansback; Mark Harrison; John Brazier; linda davies; Jacek Kopec; Carlo Marra; Deborah Symmons; Aslam H Anis
Health state utility values: a description of their development and application for rheumatic diseases.
Arthritis and rheumatism 2008;59(7):1018-26.
2008: Jonathan Daniel Karnon; Carolyn J Czoski-Murray; K Smith; C Brand; Usha Chakravarthy; Sarah Davis; Nick Bansback; Catherine Beverley; A Bird; S Harding; I Chisholm; Y C Yang
A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.
Health technology assessment (Winchester, England) 2008;12(27):iii-iv, ix-124.
2008: Allan Wailoo; Nick Bansback; Alan Brennan; Kaleb Michaud; Richard M Nixon; Fred Wolfe
Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis.
Arthritis and rheumatism 2008;58(4):939-46.
2008: Allan Wailoo; Nick Bansback; James Chilcott
Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.
Rheumatology (Oxford, England) 2008;47(2):119-20.
2008: Nick Bansback; Roberta Ara; Jonathan Daniel Karnon; Aslam H Anis
Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States.
PharmacoEconomics 2008;26(5):395-408.
2007: Nick Bansback; S Davis; John Brazier
Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.
Eye (London, England) 2007;21(12):1455-63.
2007: Nick Bansback; Carlo Marra; Aki Tsuchiya; Aslam H Anis; Daphne Guh; Tony Hammond; John Brazier
Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis.
Arthritis and rheumatism 2007;57(6):963-71.
2007: Alan Brennan; Nick Bansback; R Nixon; Jason Madan; Mark Harrison; K Watson; Deborah Symmons
Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Rheumatology (Oxford, England) 2007;46(8):1345-54.
2007: R Nixon; Nick Bansback; Alan Brennan
The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.
Rheumatology (Oxford, England) 2007;46(7):1140-7.
2007: Nick Bansback; Andreas Maetzel; Mike Drummond; Aslam H Anis; Carlo Marra; Peter Conway; Maarten Boers; Peter Tugwell; Annelies Boonen
Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis.
The Journal of rheumatology 2007;34(5):1178-83.
2007: Dean A Regier; Nick Bansback; Anne Dar Santos; Carlo A Marra
Cost-effectiveness of tumor necrosis factor-alpha antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Expert review of pharmacoeconomics & outcomes research 2007;7(2):155-69.
2007: Nick Bansback; Carolyn J Czoski-Murray; J Carlton; G Lewis; L Hughes; Mireia Espallargues; C Brand; John Brazier
Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2007;16(3):533-43.
2007: Richard M Nixon; Nick Bansback; Alan Brennan
Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis.
Statistics in medicine 2007;26(6):1237-54.
2006: Kenneth C Thomas; Bohdan Nosyk; Charles G Fisher; Marcel F Dvorak; Roy A Patchell; William F Regine; Andrew Loblaw; Nick Bansback; Daphne Guh; Huiying Sun; Aslam H Anis
Cost-effectiveness of surgery plus radiotherapy versus radiotherapy alone for metastatic epidural spinal cord compression.
International journal of radiation oncology, biology, physics 2006;66(4):1212-8.
2006: Nick Bansback; Adam Young; Alan Brennan; Josh Dixey
A prognostic model for functional outcome in early rheumatoid arthritis.
The Journal of rheumatology 2006;33(8):1503-10.
2006: Nick Bansback; Roberta Ara; N Barkham; Alan Brennan; A D Fraser; Peter Conway; Alan Reynolds; P Emery
Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
Rheumatology (Oxford, England) 2006;45(8):1029-38.
2005: Mireia Espallargues; Carolyn J Czoski-Murray; Nick Bansback; Jill Carlton; Grace M Lewis; Lindsey A Hughes; Christopher S Brand; John E Brazier
The impact of age-related macular degeneration on health status utility values.
Investigative ophthalmology & visual science 2005;46(11):4016-23.
2005: Nick Bansback; Alan Brennan; Aslam H Anis
A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis.
Expert review of pharmacoeconomics & outcomes research 2005;5(5):519-29.
2005: Nick Bansback; Alan Brennan; O Ghatnekar
Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.
Annals of the rheumatic diseases 2005;64(7):995-1002.
2005: Nick Bansback; Dean A Regier; Roberta Ara; Alan Brennan; Kamran Shojania; John M Esdaile; Aslam H Anis; Carlo A Marra
An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
Drugs 2005;65(4):473-96.
2005: Nick Bansback; A Young; Alan Brennan
The NICE reappraisal of biologics in 2005: what rheumatologists need to know.
Rheumatology (Oxford, England) 2005;44(1):3-4.
2004: Nick Bansback; Sue Ward; Jonathan Daniel Karnon
Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. How important is quality of life?
The European journal of health economics : HEPAC : health economics in prevention and care 2004;5(2):188-9.
2004: Alan Brennan; Nick Bansback
Re: Wolfe et al. Do rheumatology cost-effectiveness analyses make sense?
Rheumatology (Oxford, England) 2004;43(5):677-8.
2004: Alan Brennan; Nick Bansback; Alan Reynolds; Peter Conway
Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.
Rheumatology (Oxford, England) 2004;43(1):62-72.
2001: Myfanwy Lloyd Jones; Silvia Hummel; Nick Bansback; B Orr; MT Seymour
A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.
Health technology assessment (Winchester, England) 2001;5(25):1-128.
2001: Sue Ward; E Morris; Nick Bansback; Neill W Calvert; A Crellin; D Forman; M Larvin; D Radstone
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer.
Health technology assessment (Winchester, England) 2001;5(24):1-70.